Trials / Not Yet Recruiting
Not Yet RecruitingNCT07509801
A Study to Evaluate the Safety and Efficacy of NT-88
A Randomized, Single-center, Blinded Analysis Clinical Study to Evaluate the Safety and Efficacy of NT-88 in Patients With Heart Failure With Chronic Mildly Reduced Ejection Fraction
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Guangzhou Manjing biomedicine technology co., ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the safety and preliminary efficacy of Zuozhu Daxi in patients with chronic heart failure with mildly reduced ejection fraction
Detailed description
A randomized, single-center, blinded analysis clinical study to evaluate the safety and efficacy of NT-88 inpatients with heart failure with chronic mildly reduced ejection fraction. To evaluate the safety and preliminary efficacy of Zuozhu Daxi in patients with chronic heart failure with mildly reduced ejection fraction
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Conventional therapeutic drugs | Conventional therapeutic drugs |
| DRUG | NT-88 | Conventional therapeutic drugs+NT-88 |
Timeline
- Start date
- 2026-03-30
- Primary completion
- 2027-02-25
- Completion
- 2027-06-30
- First posted
- 2026-04-03
- Last updated
- 2026-04-03
Source: ClinicalTrials.gov record NCT07509801. Inclusion in this directory is not an endorsement.